Sign in
Active, not recruitingNo phase

Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant

Key facts

Who runs it
Materialise
Where
Belgium and Netherlands4 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
24 people, planned
Started
1 Jul 2019
Expected to end
Mar 2030
Type of study
Observational
Treatments tested
  • reversed glenoid prothesis
Record updated
8 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • patients having primary or revision shoulder joint replacement with severe glenoid bone defects
  • Patient is 18 years of age or older
  • Patient can follow the Glenius system procedure that is standard of care
  • Patient is willing to cooperate in the required post-operative therapy
  • Patient has participated in the informed consent process and has signed the EC approved informed consent form

Who cannot take part

  • Pregnant patients
  • Skeletally immature patients
  • Prisoners

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This post-market follow-up study investigates improvement in clinical and radiological outcome after reversed total shoulder arthroplasty with the patient-specific Glenius Glenoid Reconstruction system

The group in the trial

  • Treatment group

    Patients treated with a Glenius Glenoid Reconstruction System

    Treatment: reversed glenoid prothesis

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant: A Prospective Cohort Study
Record updated
8 October 2026